MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
20.18
+1.85
+10.09%
After Hours: 21.00 +0.82 +4.06% 18:57 05/12 EDT
OPEN
19.16
PREV CLOSE
18.33
HIGH
20.42
LOW
19.00
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
47.00
52 WEEK LOW
14.40
MARKET CAP
1.34B
P/E (TTM)
-7.4791
1D
5D
1M
3M
1Y
5Y
1D
2 'Strong Buy' Biotech Growth Stocks With Over 200% Upside Potential
Barchart · 13h ago
Celldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
TipRanks · 13h ago
Celldex’s Strategic Advancements and Promising Clinical Developments Drive Buy Rating
TipRanks · 15h ago
Weekly Report: what happened at CLDX last week (0505-0509)?
Weekly Report · 15h ago
Celldex Therapeutics Price Target Cut to $38.00/Share From $44.00 by UBS
Dow Jones · 3d ago
Celldex Therapeutics Is Maintained at Buy by UBS
Dow Jones · 3d ago
UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38
Benzinga · 3d ago
Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs
Dow Jones · 3d ago
More
About CLDX
More
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Recently
Symbol
Price
%Change
    EFX
  • 276.37
  • +2.39%

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.